The DNA-damaging agent lurbinectedin effectively inhibits the proliferation of human SCLC cell lines, particularly those with high SLFN11 expression, while the combination of ATR inhibitors with lurbinectedin exhibits synergistic effects in SCLC cell lines with low SLFN11 expression (50). This evidence concerns the gene ATR and small cell lung carcinoma.